Condition

Hyperprolactinemia

ClinicalTrials.gov condition label

Clinical trials8

Recruiting0

Common interventions9

Lead sponsors shown7

Clinical trials

8 shown

A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum DisordersNCT01742390 · 2013-02-01

Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With SchizophreniaNCT01852331 · 2013-01-01

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With SchizophreniaNCT01338298 · 2011-01-01

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)NCT01270711 · 2010-11-01

Clinical Efficacy and Adverse Reactions of Antipsychotic TreatmentNCT06326840 · 2010-05-31

Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and DyslipidemiaNCT00541554 · 2007-10-01

The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary EventsNCT01052948 · 2007-01-01

Risperidone-Induced Hyperprolactinemia Treated With BromocriptineNCT00315081 · 2006-05-01

Common interventions

AripiprazoleDRUG2 PlaceboDRUG2 Abilify (aripiprazole)DRUG1 BromocriptinDRUG1 MetforminDRUG1 PGD granulesDRUG1 Retrospective study-OTHER1 risperidone or paliperidoneDRUG1 Study DrugDRUG1

Leading sponsors

Pfizer2 Genovate Biotechnology Co., Ltd.,1 Si Tianmei1 Taipei Medical University Hospital1 The University of Hong Kong1 University Hospital, Bonn1 University of Maryland, Baltimore1

Trial status mix

COMPLETED5

UNKNOWN3

Phase mix

NA2

PHASE42

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.